When
07/16/24 8:30 AM
07/16/24 5:30 PM
America/New_York
Pediatric Inclusion Roundtable
Join Leavitt Partners, LLC, and Friedreich’s Ataxia Research Alliance (FARA) for the Pediatric Inclusion Roundtable: Effective Inclusion of Children Early in Clinical Trials. The program will engage all stakeholders regarding the need for including children earlier in clinical development, the requirements for early inclusion, and the most effective means for meeting those requirements. <br>
<br>
Attendees will hear from FDA and NIH leadership on their vision for effective pediatric inclusion, followed by multi-stakeholder panel discussions centered around FDA’s three medical product centers: CDER, CBER, and CDRH. <a href="https://hma.connect.space/accounts/events/pediatric-inclusion-roundtable/attachments/3659/download">Click here</a> for a detailed agenda.<br>
<br>
The Roundtable is in-person at Leavitt Partners’ Washington, D.C. office, with a virtual option. Participants will include FDA, NIH, industry, patient advocacy organizations, academic clinicians, regulatory advisors, clinical trial designers, bioethicists, and others interested in learning more.<br>
<br>
In-person registration space is limited. Registration closes at 5:00PM on July 15.
Leavitt Partners, LLC 601 New Jersey Avenue Northwest, Suite 350, Washington, DC 20001 United States
Effective Inclusion of Children Early in Clinical Trials
sarah.shonk@wakely.com
false
MM/DD/YYYY
Jul
16
Tue, Jul 16, 2024, 8:30 AM — 5:30 PM EDT
Where
601 New Jersey Avenue Northwest, Suite 350, Washington, DC 20001 United States
Join Leavitt Partners, LLC, and Friedreich’s Ataxia Research Alliance (FARA) for the Pediatric Inclusion Roundtable: Effective Inclusion of Children Early in Clinical Trials. The program will engage all stakeholders regarding the need for including children earlier in clinical development, the requirements for early inclusion, and the most effective means for meeting those requirements.
Attendees will hear from FDA and NIH leadership on their vision for effective pediatric inclusion, followed by multi-stakeholder panel discussions centered around FDA’s three medical product centers: CDER, CBER, and CDRH. Click here for a detailed agenda.
The Roundtable is in-person at Leavitt Partners’ Washington, D.C. office, with a virtual option. Participants will include FDA, NIH, industry, patient advocacy organizations, academic clinicians, regulatory advisors, clinical trial designers, bioethicists, and others interested in learning more.
In-person registration space is limited. Registration closes at 5:00PM on July 15.
Attendees will hear from FDA and NIH leadership on their vision for effective pediatric inclusion, followed by multi-stakeholder panel discussions centered around FDA’s three medical product centers: CDER, CBER, and CDRH. Click here for a detailed agenda.
The Roundtable is in-person at Leavitt Partners’ Washington, D.C. office, with a virtual option. Participants will include FDA, NIH, industry, patient advocacy organizations, academic clinicians, regulatory advisors, clinical trial designers, bioethicists, and others interested in learning more.
In-person registration space is limited. Registration closes at 5:00PM on July 15.